You are here

ESMO

Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data

Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data

BioSpace

prostate cancer

radiopharmaceuticals

Flag link:

ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear

ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear

Fierce Biotech

clinical trials

non-small cell lung cancer

Flag link:

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

BioSpace

Bristol Myers Squibb

PD-1 inhibitors

Flag link:

ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen

ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen

Fierce Biotech

prostate cancer

antibody-drug conjugate

Flag link:

Merck's early KRAS data suggest combination-friendly safety

Merck's early KRAS data suggest combination-friendly safety

Fierce Biotech

KRAS inhibitors

Flag link:

ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists

ESMO: Rain in Spain doesn’t dampen spirits of 33,000 oncologists

Fierce Pharma

Flag link:

ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up

ESMO: AstraZeneca proposes adding Lynparza to Imfinzi as endometrial cancer race heats up

Fierce Pharma

endometrial cancer

Flag link:

ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer

ESMO: Seagen and Genmab's Tivdak keeps cervical cancer patients alive longer

Fierce Pharma

cervical cancer

antibody-drug conjugate

Flag link:

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer

ESMO: In PD-1 battle GSK waged on Merck, Jemperli appears to show survival edge over Keytruda in lung cancer

Fierce Pharma

nonsquamous non-small cell lung cancer

Flag link:

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

non-small cell lung cancer

Flag link:

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

Fierce Pharma

Flag link:

Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer

Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer

BioSpace

non-small cell lung cancer

Flag link:

After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review

After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review

Fierce Pharma

Gilead Sciences

priority review

Flag link:

Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done

Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done

Fierce Pharma

Flag link:

ESMO 2022 movers – KRAS backfires

ESMO 2022 movers – KRAS backfires

EP Vantage

KRAS inhibitors

Relay Therapeutics

Clovis Oncology

Ayala Pharmaceuticals

Mirati Therapeutics

Flag link:

Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO

Regeneron Highlights Plug-and-Play Oncology Strategy at ESMO

BioSpace

Flag link:

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining

ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining

Fierce Pharma

head and neck cancer

Flag link:

A Post-mortem on the Failed Nektar-BMS Partnership at ESMO

A Post-mortem on the Failed Nektar-BMS Partnership at ESMO

BioSpace

Bristol Myers Squibb

Nektar Therapeutics

Flag link:

Pages